TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03121677

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Cause of deathDrug or device supply Automatic label, confidence 0.9, unverified. How labels are made.
“Vaccine manufacturing has been suspended”

The sponsor’s own words in the registry.

Life of this trial

20172018201920202021202220232024Registered2017-04-17Started2018-10-16Primary completion2020-09-24Stopped2023-08-07

Vital statistics

Status
Terminated
Phase
Phase 1
Sponsor
Washington University School of Medicine
Sponsor type
University, hospital or other
Conditions
Follicular Lymphoma
Interventions
Personalized tumor vaccine; Poly ICLC; Nivolumab; Peripheral blood draws; Leukapheresis; Rituximab
Participants
4
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.